## RESEARCH

# Additional file 3: STROBE Checklist

Andrei S Morgan<sup>1\*</sup>, Neil Marlow<sup>1</sup>, Elizabeth S Draper<sup>3</sup>, Zarko Alfirević<sup>4</sup>, Enid M Hennessy<sup>5</sup> and Kate Costeloe<sup>2</sup>

\*Correspondence: andrei.morgan@ucl.ac.uk

<sup>1</sup>Institute for Womens' Health, UCL, 74 Huntley Street, WC1E 6AU, London, UK Full list of author information is available at the end of the article

## **1 STROBE Statement checklist**

The following table contains the STROBE checklist of items to be included in reports of cohort studies alongside a reference to where in the article the information may be found.

STROBE checklist for "Impact of obstetric interventions on condition at birth in extremely preterm babies: evidence from a national cohort study"

	Item No	Recommendation	Page (notes)
Title and ab- stract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 1 (Title)
		(b) Provide in the abstract an informative and balanced sum- mary of what was done and what was found	Page 1
Introduction			
Background/ration	al¢2	Explain the scientific back- ground and rationale for the investigation being reported	Page 2 (background section)
Objectives	3	State specific objectives, includ- ing any prespecified hypotheses	Page 2 (final paragraph of back- ground)
Methods			
Study design	4	Present key elements of study de- sign early in the paper	Page 2 (methods)
Setting	5	Describe the setting, locations, and relevant dates, including pe- riods of recruitment, exposure,	Page 2 (methods)
Participants	6	follow-up, and data collection (a) Give the eligibility criteria, and the sources and methods of selection of participants. De- scribe methods of follow-up	Page 2 (methods)
		(b) For matched studies, give matching criteria and number of exposed and unexposed	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modi- fiers. Give diagnostic criteria, if applicable	Page 3 (study variables)
Data sources/measureme	8 <sup>a</sup> nt	For each variable of interest, give sources of data and details of methods of assessment (measure- ment). Describe comparability of assessment methods if there is more than one group.	Pages 2 (methods) and 3 (study variables)

Continued on next page...

	Item No	Recommendation	Page (notes)
Bias	9	Describe any efforts to address potential sources of bias	Page 4 (final paragraph of 'statisti- cal methods')
Study size	10	Explain how the study size was arrived at	Pages 2 (methods) and Additional file 1: Figure 1. Additional informa- tion relating to this is provided in the other figures (figure 1, page 17 and Additional file 1: Figures 2-4)
Quantitative vari- ables	11	Explain how quantitative vari- ables were handled in the analy- ses. If applicable, describe which groupings were chosen and why	Page 3 (study variables)
Statistical meth- ods	12	(a) Describe all statistical meth- ods, including those used to con- trol for confounding	Page 4 (statistical methods)
		(b) Describe any methods used to examine subgroups and inter- actions	Page 4 (statistical methods, second paragraph)
		(c) Explain how missing data were addressed	Page 5 (third paragraph)
		(d) If applicable, explain how loss to follow-up was addressed	N/A
		(e) Describe any sensitivity anal- yses	Page 4 (third paragraph)
Results			
Participants	13 <sup>a</sup>	(a) Report numbers of individ- uals at each stage of study—eg numbers potentially eligible, ex- amined for eligibility, confirmed eligible, included in the study, completing follow-up, and anal- ysed	Page 4 (Results: "population" sec- tion) and Additional file 1: Figure 1. Additional information relating to this is provided in the other fig- ures (figure 1, page 15, and Addi- tional file 1: figures 2-4)
		(b) Give reasons for non- participation at each stage	Additional file 1: Figure 1
		(c) Consider use of a flow dia- gram	Figure 1 (pages 17) and Additiona file 1: figures 1-4
Descriptive data	14 <sup>a</sup>	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential con- founders	Pages 4 (Results: "population" sec- tion), 6 (table 1) and Additional file 2: Table 1
		(b) Indicate number of partici- pants with missing data for each variable of interest	Pages 4 (Results: "population" section), 6 (table 1) and Additional file 2: Table 1
		(c) Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	$15^{\mathrm{a}}$	Report numbers of outcome events or summary measures over time	Page 5 (Results: "population" section, third paragraph) and page 6 (table 1)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder- adjusted estimates and their pre- cision (eg, 95% confidence in- terval). Make clear which con- founders were adjusted for and why they were included	Pages 4-11 (Entire "results" sec- tion. Unadjusted results are pre- sented first, with confounder ad- justed estimates listed under each of the main exposures: antenata steroids, tocolysis and mode of de- livery)
		(b) Report category boundaries when continuous variables were categorized	Additional file 2: Table 1
		(c) If relevant, consider trans- lating estimates of relative risk into absolute risk for a meaning- ful time period	N/A

## Strobe checklist (continued)

Continued on next page...

	Item No	Recommendation	Page (notes)
Other analyses	17	Report other analyses done—eg analyses of subgroups and inter- actions, and sensitivity analyses	Pages 8-11 (sensitivity analyses, discussed under each of the respec- tive exposures)
Discussion			
Key results	18	Summarise key results with reference to study objectives	Page 1 (principal findings)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and mag- nitude of any potential bias	Pages 11-13 (Strengths and limitations of this study)
Interpretation	20	Give a cautious overall interpre- tation of results considering ob- jectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evi- dence	Pages 13-14 (Study findings in con- text)
Generalisability	21	Discuss the generalisability (ex- ternal validity) of the study re- sults	Pages 13-14 (Study findings in con- text)
Other information	on		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 14 (Funding)

### Strobe checklist (continued)

 $^{\rm a}$  Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

#### Author details

<sup>1</sup>Institute for Womens' Health, UCL, 74 Huntley Street, WC1E 6AU, London, UK. <sup>2</sup> Homerton Hospital, London, UK. <sup>3</sup> University of Leicester, Leicester, UK. <sup>4</sup> University of Liverpool, Liverool, UK. <sup>5</sup> The Wolfson Institute, Queen Mary University of London, London, UK.

### References